Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160449 | 0.90 | AKR1B1 (0.45) | AKR1B1AKR1A1PTGDR2CHRM5 | |
| SCHEMBL4164402 | 0.90 | ADAMTS5 (0.40) | AKR1B1CHRM5TP53MAPTSMN1; SMN2 | |
| SCHEMBL4172070 | 0.87 | SCN9A (0.44) | TP53MAPTSCN9A | |
| SCHEMBL4255735 | 0.84 | TP53 (0.52) | AKR1B1AKR1A1PTGDR2TP53MAPT | |
| SCHEMBL10960512 | 0.84 | AKR1A1 (0.47) | AKR1B1AKR1A1PTGDR2TP53MAPT | |
| SCHEMBL4169840 | 0.82 | LMNA (0.39) | AKR1B1AKR1A1CHRM5SMN1; SMN2 | |
| SCHEMBL3954635 | 0.82 | PTGDR2 (0.39) | AKR1B1PTGDR2CHRM5 | |
| SCHEMBL4171615 | 0.81 | AKR1B1 (0.44) | AKR1B1AKR1A1PTGDR2TP53MAPT | |
| SCHEMBL4258971 | 0.80 | TP53 (0.45) | AKR1B1AKR1A1PTGDR2TP53MAPT | |
| SCHEMBL4163964 | 0.76 | AKR1B1 (0.41) | AKR1B1AKR1A1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV5, TRPV2 | AKR1B1 344/4885AKR1A1 310/4885PTGDR2 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.